Gubra A/S Opens Its First US Office in Boston -October 24, 2023 at 01:30 am EDT | MarketScreener
mfn_news Archive | Page 5 of 7 | Gubra
Gubra wins Entrepreneur of the Year for the second year in a row - DTU Science Park
Gubra A/S acquired Minigut Aps. -June 28, 2023 | MarketScreener
Effects of liraglutide and sibutramine on food intake, palatability, body weight and glucose tolerance in the gubra DIO-rats | Acta Pharmacologica Sinica
Andrew James Samson on LinkedIn: #narcolepsy #gubra #neuroscience #drugdiscovery #sleep #peptides
The Hub | Gubra ApS
Gubra announces intention to launch an Initial Public Offering on Nasdaq Copenhagen and raise capital to support its growth strategy | Gubra
The Hub | Gubra ApS
Commute by Gubra - Apps on Google Play
BI, Gubra to Develop Next-Generation Obesity Treatments - Research & Development World
Gubra A/S announces signing of collaboration agreement with Hemab ApS | Gubra
Boehringer, Gubra In $250M Obesity Collaboration | Contract Pharma
Commute by Gubra by Gubra ApS
Gubra A/S : Shareholders Board Members Managers and Company Profile | DK0062266474 | MarketScreener
Bayer: Peptide deal with Gubra - European Biotechnology
Gubra ApS and Silence Therapeutics plc collaborate to develop RNAi therapies against novel liver-directed targets from Gubra's streaMLine platform | Gubra
GUBRA APS innovation strategy - GoodIP
Gubra - Investor Relations
PDF) Effects of liraglutide and sibutramine on food intake, palatability, body weight and glucose tolerance in the gubra DIO-rats
Gubra Aps - Hørsholm, Denmark - Local Business | Facebook
GUBRA APS DK 1 Aktie: Aktienkurs & Charts | comdirect Informer
GUBRA APS innovation strategy - GoodIP
